Understand the source comparison
Peptides vs Hormonal Therapies: When Each Approach Matters
Peptides help with female sexual health when the underlying issue is neurological rather than hormonal. Bremelanotide and oxytocin are most effective in women with normal estrogen and testosterone levels but diminished desire. A pattern common in younger preme
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Peptides help with female sexual health when the underlying issue is neurological rather than hormonal. Bremelanotide and oxytocin are most effective in women with normal estrogen and testosterone levels but diminished desire. A pattern common in younger premenopausal women, those using hormonal contraceptives that suppress endogenous testosterone, or women experiencing desire concerns secondary to stress or relationship issues. These women often report intact physical arousal (vaginal lubrication, clitoral sensitivity) but absent or diminished mental interest in sex.
- Hormone therapy. Typically testosterone (off-label in women) or local estrogen. Addresses peripheral symptoms: vaginal dryness, pain during intercourse, reduced genital sensitivity, and decreased spontaneous lubrication. Postmenopausal women, those with premature ovarian insufficiency, or women who have undergone bilateral oophorectomy are most likely to benefit from hormonal intervention. Testosterone supplementation in particular has shown consistent improvements in desire and arousal in postmenopausal women, with an effect size larger than PT-141 in that population. But it comes with metabolic and cardiovascular considerations that limit long-term use.
- The Endocrine Society's 2019 clinical practice guideline on androgen therapy in women states that testosterone is 'probably effective' for treating HSDD in postmenopausal women but should not be used in premenopausal women due to insufficient evidence and unknown long-term risks. PT-141, by contrast, is FDA-approved specifically for premenopausal women and carries no hormonal side effects. Making it a first-line option when hormonal therapy is contraindicated or ineffective.
- Combination approaches may offer the best outcomes for women with both central and peripheral dysfunction. A woman experiencing vaginal atrophy (requiring local estrogen) and absent desire (potentially responsive to PT-141) may need both interventions. Our team has reviewed research suggesting that sequential therapy. Addressing tissue-level symptoms first with local estrogen, then adding neurological modulation with peptides once pain is resolved. Produces higher satisfaction rates than either intervention alone. Pain during intercourse creates anticipatory anxiety that suppresses desire regardless of melanocortin activity; removing the pain first allows PT-141's effects to manifest without competing inhibitory signals.